The event was a post-results earnings conference call to discuss the company's financial performance for Q2 and H1 FY 2027, held on Monday, November 02, 2026.
Management participants included Mr. Vimal Kumar (Managing Director), Mr. Surendra Sai (Executive Director), Mr. Sanjeev Bajaj (Chief Financial Officer), and Mr. Vikas Jain (Vice President, Business Operations).
The transcript of the earnings conference call was submitted to the exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and is also available on the company's website at www.bestagrolife.com.
The discussion covered Q2 FY27 financial results: Revenue of ₹407 crores (down 21% YoY from ₹517 crores), EBITDA of ₹101 crores (up 30% YoY from ₹78 crores), and PAT of ₹57 crores (up 48% YoY from ₹39 crores). H1 FY27 results: Revenue of ₹803 crores (down 11% YoY from ₹898 crores), EBITDA of ₹178 crores (up 45% YoY from ₹123 crores), and PAT of ₹98 crores (up 67% YoY from ₹59 crores).
Gross margin improved to 45% in Q2 FY27 from 33% in Q2 FY26, and to 41% in H1 FY27 from 31% in H1 FY26, attributed to a strategic shift towards a patented product portfolio.
Operating expenses (excluding finance costs and depreciation) reduced by 12% in Q2 FY27 to ₹81 crores from ₹92 crores YoY, and by 5% in H1 FY27 to ₹149 crores from ₹157 crores YoY.
Management attributed the revenue decline to a challenging Kharif season with uneven monsoon patterns, delayed and uneven sowing, reduced crop acreages, and cautious farmer spending, but emphasized improved profitability through product mix changes.
The company launched two new patented products during the period: Midcotin (a fungicide and insecticide combination for paddy) and SECTOR (an insecticide for pomegranate and chili).
International business updates included a 47 MT shipment to Sudan (valued at ~₹5 crores), registration of patented product Ronfen in Nepal, progress on patent applications in UAE, Vietnam, Sri Lanka, Philippines, and Egypt, and the incorporation of a step-down subsidiary in Brazil.
The company received 13 CIB registrations in the quarter across different categories.
Management stated they have created higher provisions for sales returns in H2 to avoid surprises, and expect H2 FY27 to be profitable without losses.
Regarding balance sheet, long-term borrowings increased by ~₹50 crores due to availing a government facility (20% additional limit) provided in context of the Israel-Iran war impact on inventory costs, with a 1-year moratorium and 5-year repayment at 9.5-10% interest.
The company addressed income tax assessments related to a 2023 raid, noting that 95% of cases are closed with zero liability, and expects refunds of ~₹15 crores in the next 1-1.5 months (₹5 crores already received by subsidiary Seedlings India).
No specific financial guidance was provided for H2 revenue, but management emphasized focus on profitability and stated that FY2025-26 was the "bottomed out" year.
The call included Q&A sessions with analysts Hemant, Saket Kapoor, and Aditya, covering topics like generic vs patented product mix, sales return strategies, international business, tax issues, balance sheet strength, and cost of funds.
Additional Notes Section
The document is a regulatory filing containing the transcript of the earnings conference call.
Financial data was extensively disclosed in the transcript, including revenue, EBITDA, PAT, margins, and operational metrics.
The filing includes standard forward-looking statement disclaimer that the conference call may contain forward-looking statements based on beliefs and opinions of the company as of the call date.
